{"id":"3fafe195-c020-5dc8-9742-a1e5bdff2563","stable_key":"44737fa3-b335-53f4-a644-b9878d4416ac:creatine-parkinson-negative","predicate":"did_not_improve","statement":"The trial was stopped for futility; creatine did not improve the primary clinical progression comparison (P=0.45).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"4ff3f5fc-b4c2-515d-8c1a-e0283208dc9a","mechanism_event_label":"Long-term testing did not confirm the hoped-for clinical benefit for Parkinson disease.","subject":{"id":"399b373f-0034-5f2b-83b7-637eb2678c83","slug":"creatine-monohydrate","display_name":"Creatine monohydrate","entity_type_key":"small_molecule"},"object":{"id":"64ace8e2-55de-5ab7-9404-3d82feb535a3","slug":"parkinson-clinical-progression","display_name":"Parkinson disease clinical progression","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4ff3f5fc-b4c2-515d-8c1a-e0283208dc9a","stable_key":"44737fa3-b335-53f4-a644-b9878d4416ac:creatine-parkinson-negative-event","event_type":"observed_intervention","label":"Long-term testing did not confirm the hoped-for clinical benefit for Parkinson disease.","description":"The trial was stopped for futility; creatine did not improve the primary clinical progression comparison (P=0.45).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"399b373f-0034-5f2b-83b7-637eb2678c83","slug":"creatine-monohydrate","display_name":"Creatine monohydrate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"64ace8e2-55de-5ab7-9404-3d82feb535a3","slug":"parkinson-clinical-progression","display_name":"Parkinson disease clinical progression","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/creatine-research/25668262.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419\", \"start_char\": 0, \"end_char\": 2637, \"text_sha256\": \"f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Multicenter double-blind randomized NET-PD LS-1 trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Creatine monohydrate 10 g/day; median follow-up four years; planned five-year outcome","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Stopped early for futility; distinguishes intended follow-up from actual median duration.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Creatine research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"creatine","display_name":"Creatine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"1741 people with early treated Parkinson disease","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Long-term testing did not confirm the hoped-for clinical benefit for Parkinson disease.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[creatine-p25668262] Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25668262/ DOI: 10.1001/jama.2015.120","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Composite clinical progression","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"de19a4ab-4dcf-5f9e-a612-8da277ae7cc0","evidence_kind":"source_excerpt","locator":"Lines 1140-1151","start_line":1140,"end_line":1151,"excerpt":"### creatine-parkinson-negative\nThe trial was stopped for futility; creatine did not improve the primary clinical progression comparison (P=0.45).\nCondition category: normal\nnutrient_topic: Creatine research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Long-term testing did not confirm the hoped-for clinical benefit for Parkinson disease.\norganism: 1741 people with early treated Parkinson disease\ntissue_or_cell_type: Composite clinical progression\nexperimental_model: Multicenter double-blind randomized NET-PD LS-1 trial\nlimitations: Stopped early for futility; distinguishes intended follow-up from actual median duration.\nexposure: Creatine monohydrate 10 g/day; median follow-up four years; planned five-year outcome\nevidence_span: {\"source_cache\": \"artifacts/creatine-research/25668262.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419\", \"start_char\": 0, \"end_char\": 2637, \"text_sha256\": \"f671e1277dae81047694ee994f7375030d1b744b83a5a7ffcf410b13b69cd419\"}\n[creatine-p25668262] Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25668262/ DOI: 10.1001/jama.2015.120","model_system":"Multicenter double-blind randomized NET-PD LS-1 trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [creatine-p25668262] Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25668262/ DOI: 10.1001/jama.2015.120","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"70358046-c5c3-5e9a-9fc9-eb01c3fff88b","stable_key":"import-44737fa3-b335-53f4-a644-b9878d4416ac","title":"Creatine: synthesis, transport, phosphocreatine energetics and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"548237d3e98a73a7dc02181807921fdd8b902adcee46248792258a761593eda9","revision_id":"88738255-8028-52fb-9c12-0fe92d8ce367","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}